Hybio Pharmaceutical Co., Ltd.

Equities

300199

CNE1000011T7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 12/06/2024 BST 5-day change 1st Jan Change
10.73 CNY -1.56% Intraday chart for Hybio Pharmaceutical Co., Ltd. +9.38% -20.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection MT
Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical MT
Hybio Pharmaceutical Gets Nod to Market Ganirelix Acetate Injection MT
Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection MT
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5% MT
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4% MT
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6% MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray MT
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client MT
Hybio Pharmaceutical Co., Ltd.(XSEC:300199) added to S&P Global BMI Index CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 254.12 million in funding CI
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient MT
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery MT
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules MT
Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million. CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin. CI
Hybio Pharma’s COVID-19 Nasal Spray Wins FDA Nod For Clinical Trial MT
Li Xiulan agreed to acquire a 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin for approximately CNY 450 million. CI
Chart Hybio Pharmaceutical Co., Ltd.
More charts
Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Company’s products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.
More about the company
  1. Stock Market
  2. Equities
  3. 300199 Stock
  4. News Hybio Pharmaceutical Co., Ltd.
  5. Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW